PMID- 35324455
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 2049-3614 (Print)
IS  - 2049-3614 (Electronic)
IS  - 2049-3614 (Linking)
VI  - 11
IP  - 5
DP  - 2022 May 11
TI  - Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 
      Florentine database.
LID - e210456 [pii]
LID - 10.1530/EC-21-0456 [doi]
AB  - Multiple endocrine neoplasia type 1 (MEN1) is a rare, inherited cancer syndrome 
      characterized by the development of multiple endocrine and non-endocrine tumors. 
      MEN1 patients show a reduction of bone mass and a higher prevalence of early 
      onset osteoporosis, compared to healthy population of the same age, gender, and 
      ethnicity. During the monitoring and follow-up of MEN1 patients, the attention of 
      clinicians is primarily focused on the diagnosis and therapy of tumors, while the 
      assessment of bone health and mineral metabolism is, in many cases, marginally 
      considered. In this study, we retrospectively analyzed bone and mineral 
      metabolism features in a series of MEN1 patients from the MEN1 Florentine 
      database. Biochemical markers of bone and mineral metabolism and densitometric 
      parameters of bone mass were retrieved from the database and were analyzed based 
      on age ranges and genders of patients and presence/absence of the three main 
      MEN1-related endocrine tumor types. Our evaluation confirmed that patients with a 
      MEN1 diagnosis have a high prevalence of earlyonset osteopenia and osteoporosis, 
      in association with levels of serum and urinary markers of bone turnover higher 
      than the normal reference values, regardless of their different MEN1 tumors. 
      Fifty percent of patients younger than 26 years manifested osteopenia and 8.3% 
      had osteoporosis, in at least one of the measured bone sites. These data suggest 
      the importance of including biochemical and instrumental monitoring of bone 
      metabolism and bone mass in the routine medical evaluation and follow-up of MEN1 
      patients and MEN1 carriers as important clinical aspects in the management of the 
      syndrome.
FAU - Marini, Francesca
AU  - Marini F
AD  - Department of Experimental and Clinical Biomedical Sciences, University of 
      Florence, Florence, Italy.
AD  - F.I.R.M.O. Italian Foundation for the Research on Bone Diseases, Florence, Italy.
FAU - Giusti, Francesca
AU  - Giusti F
AD  - Department of Experimental and Clinical Biomedical Sciences, University of 
      Florence, Florence, Italy.
FAU - Iantomasi, Teresa
AU  - Iantomasi T
AD  - Department of Experimental and Clinical Biomedical Sciences, University of 
      Florence, Florence, Italy.
FAU - Cioppi, Federica
AU  - Cioppi F
AD  - University Hospital of Florence, Azienda Ospedaliero Universitaria Careggi 
      (AOUC), Florence, Italy.
FAU - Brandi, Maria Luisa
AU  - Brandi ML
AUID- ORCID: 0000-0002-8741-0592
AD  - F.I.R.M.O. Italian Foundation for the Research on Bone Diseases, Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220511
PL  - England
TA  - Endocr Connect
JT  - Endocrine connections
JID - 101598413
PMC - PMC9175581
OTO - NOTNLM
OT  - bone modeling
OT  - bone tissue
OT  - bone turnover
OT  - mineral metabolism
OT  - multiple endocrine neoplasia type 1 (MEN1)
OT  - osteoporosis
EDAT- 2022/03/25 06:00
MHDA- 2022/03/25 06:01
PMCR- 2022/03/23
CRDT- 2022/03/24 17:23
PHST- 2022/03/11 00:00 [received]
PHST- 2022/03/23 00:00 [accepted]
PHST- 2022/03/25 06:00 [pubmed]
PHST- 2022/03/25 06:01 [medline]
PHST- 2022/03/24 17:23 [entrez]
PHST- 2022/03/23 00:00 [pmc-release]
AID - e210456 [pii]
AID - EC-21-0456 [pii]
AID - 10.1530/EC-21-0456 [doi]
PST - epublish
SO  - Endocr Connect. 2022 May 11;11(5):e210456. doi: 10.1530/EC-21-0456.